AEON Biopharma, Inc.
AEON•NYSEAMERICAN•Healthcare•Biotechnology

About AEON Biopharma

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.

Company Information

SectorHealthcare
IndustryBiotechnology
CEORobert Bancroft
Employees5
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNYSEAMERICAN (NYSEAMERICAN)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock
Share ClassClass A Shares

Contact Information

Websitewww.aeonbiopharma.com
Phone949 354 6499
Address
5 Park Plaza, Suite 1750 Irvine, California 92614 United States

Corporate Identifiers

CIK0001837607
CUSIP00791X209
ISINUS00791X2099
EIN85-3940478
SIC2834

Leadership Team & Key Executives

Robert Bancroft
President, Chief Executive Officer and Director
Alex Wilson
Executive Vice President, Chief Legal Officer and Corporate Secretary
Dr. Chad K. Oh M.D.
Chief Medical Officer
Jennifer Sy
Chief Accounting Officer and Principal Financial Officer